483
Bora Pharmaceuticals (frmly: TWI Pharmaceuticals, Inc.)Bora Pharmaceuticals (frmly: TWI Pharmaceuticals, Inc.) – FDA 483, Mar 27, 2026
Record Details
Bora Pharmaceutical Laboratories Inc. Zhongli Plant in Taoyuan City, Taiwan, was cited for significant deficiencies in its drug manufacturing operations. The inspection revealed critical issues including inadequate cleaning validation, repeated failures to investigate out-of-specification results and foreign matter, and insufficient controls over computerized systems. Additionally, the firm demonstrated poor management of manufacturing materials, indicating a systemic lack of quality control.
- Inspection date
- March 27, 2026
- Product type
- drugs
View Company Profile
ID · 5f094a61-bb93-4e50-adb8-b4dd767fb759
Other documents for Bora Pharmaceuticals (frmly: TWI Pharmaceuticals, Inc.)
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.